Document:

Agreement

 Exhibit 10.61 
 LV ADMINISTRATIVE SERVICES, INC. 
 as Administrative and Collateral Agent

 875 THIRD AVENUE, 3RD FLOOR 
 NEW YORK, NEW YORK 10022 
 October 19, 2011 

Accentia Biopharmaceuticals, Inc. 
 324 S. Hyde
Park Ave. 
 Suite 350 
 Tampa FL 33606

 Attn: President 

Re: Sale of Analytica and Agreement for Pre-payment of Accentia Term Notes 
 Ladies and Gentlemen: 
 Reference is made to (a) that certain Term
Loan & Security Agreement dated as of November 17, 2010 (as amended, supplemented, restated or modified from time to time, the “Term Loan & Security Agreement”) by and between LV Administrative Services, Inc.
(“LV”) as Agent for and on behalf of each of the creditor parties named therein (the “Lenders”) and Accentia Biopharmaceuticals, Inc. (“Accentia”); and (b) the Ancillary Agreements (as defined
in the Term Loan & Security Agreement). Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Term Loan & Security Agreement or the Ancillary Agreements, as applicable. 

WHEREAS, Accentia has an opportunity to sell Analytica and to pre-pay a portion of the Accentia Term Notes; and 

WHEREAS, pursuant to Section 42 of the Term Loan & Security Agreement, LV has the authority to enter into this Letter
Agreement modifying, amending and waiving certain terms and provisions of the Term Loan & Security Agreement and the Ancillary Agreements, which action will constitute the valid and binding action on behalf of each of the Lenders.

 In consideration of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Accentia
and LV as designated Agent for and on behalf of the Lenders hereby agree to, and acknowledge, the following: 
  

	1.	SALE OF ANALYTICA AND PRE-PAYMENT OF ACCENTIA TERM NOTES. 

 The items set forth in Sections 1(A) to 1(F) shall immediately and automatically take place upon the satisfaction of all of the following conditions on or before December 31, 2011: (i) Accentia
closes the sale of the assets or stock of Analytica to a non-affiliated third party on before December 31, 2011; and (ii) LV receives a minimum of $4 million representing all of the cash proceeds from the closing of the sale of Analytica
(the “Note Pre-payment”). For clarification, the cash proceeds from the closing of the sale of Analytica shall not include any future, contingent portions of the purchase price not paid at closing (the “Earn-out Payments”) or any
cash, deposits or accounts receivable on the books of Analytica and retained by Accentia as part of the closing. 

	 	A.	Analytica, all assets of Analytica, all guaranties made by Analytica, Analytica’s IP and any and all other obligations of Analytica or concerning the assets of
Analytica under any and all agreements with LV and/or the Lenders, including but not limited to all security agreements, pledge agreements, guarantees and stock pledge agreements, shall be automatically, immediately and irrevocably released by LV on
its behalf and on behalf of all Lenders. For clarification, immediately and automatically upon the receipt by LV of the Note Pre-payment, Analytica and all of the assets of Analytica shall be free from any security interest or claim by LV or Lenders
whether arising under from the Term Loan & Security Agreement and the Ancillary Agreements or otherwise. Specifically, but not by way of limitation of the foregoing, the Grant of Security in Intellectual Property (of Analytica), the
Guaranty (of Analytica), and the Stock Pledge Agreement (of Analytica Common Stock), each of which are Ancillary Agreements, shall be automatically terminated and of no further force or effect upon the receipt by LV of the Note Pre-payment. In
furtherance of the foregoing, LV as Agent for and on behalf of each of the Lenders shall immediately upon receipt of the Note Pre-payment: (i) execute and file the UCC-3 attached hereto as an exhibit, (ii) return all shares of Analytica
common stock and related stock powers held by LV as collateral, and (iii) execute and deliver to Accentia any additional documents requested by Accentia to carry out and effectuate the termination of security and collateral interests in or
against Analytica and its assets and stock. 

  

	 	B.	LV on its behalf and on behalf of the Lenders hereby irrevocably waive, release and give up all rights to or interests in any and all Earn-out Payments included as part
of the purchase price for the sale of Analytica. 

  

	 	C.	The remaining balance due under the Accentia Term Notes after the Note Pre-payment with a current maturity date of November 17, 2012 (including any accrued
but unpaid interest) shall automatically become due and payable on November 17, 2013. For clarification, upon receipt by LV of the Note Pre-payment, the maturity date of the Accentia Term Notes will by virtue of this Letter Agreement be
automatically extended for one year beyond their current maturity date. 

  

	 	D.	Notwithstanding the release by LV and Lenders of all liens on the Analytica assets, guaranties of Analytica, and the pledge of the Analytica Common Stock, LV and
Lenders will continue to hold the first security interest in 20,115,818 shares of the common stock of Biovest International, Inc. which have been pledged by Accentia as collateral for the Accentia Term Notes. 

 

	 	E.	The requirement set forth pursuant to Section 2.2(b) of the Accentia Term Notes that thirty percent (30%) of any capital raised by Accentia be paid to LV
on behalf of Lenders to pre-pay the Accentia Term Notes in the aggregate amount for all Term Notes is hereby automatically and irrevocably waived until the earlier of i) March 31, 2012 or ii) the date on which a maximum of $5.0 million in new
capital is raised by Accentia (the “$5.0 Million Carve-Out”). For purposes of clarity and by way of example, if prior to March 31, 2012, Accentia were to raise new capital totaling $6.0 million, Accentia will be required to
pre-pay the Accentia Term Notes (in the aggregate) only in the amount of $300,000 ($6.0 million less the $5.0 Million Carve-Out multiplied by 30%). It is expressly agreed and acknowledged that for purposes of this provision any funds received
by Accentia on account of the sale of Analytica shall not be counted toward the $5.0 Million Carve-Out. 

	 	F.	All other terms and conditions of the Term Loan & Security Agreement and the Ancillary Agreements not specifically amended hereby shall remain in full force
and effect. 

  

	3.	MISCELLANEOUS. 

  

	 	A.	Except as specifically amended herein, the Term Loan & Security Agreement and each Ancillary Agreement shall remain in full force and effect, and are hereby
ratified and confirmed. The execution, delivery and effectiveness of this Letter Agreement shall not operate as a waiver of any right, power or remedy, nor constitute a waiver of any provision of the Term Loan & Security Agreement or any
Ancillary Agreement except as otherwise provided herein. This Letter Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, executors, administrators, successors and assigns and shall be governed
by and construed in accordance with the laws of the State of New York. 

  

	 	B.	If Accentia does not close the sale of Analytica on or before December 31, 2011, this Letter Agreement shall automatically terminate and be of no continuing
effect. 

 [Remainder of Page Intentionally Left Blank] 

 This Letter Agreement may be executed by the parties hereto in one or more counterparts,
each of which shall be deemed an original and all of which when taken together shall constitute one and the same agreement. Any signature delivered by a party by facsimile or ‘pdf’ transmission shall be deemed to be an original signature
hereto. 
  

			
	Very truly yours,
	
	LV ADMINISTRATIVE SERVICES, INC., as administrative/collateral agent for the Lenders named below
		
	By:	 	 /s/ Patrick Regan

	Name: Patrick Regan
	Title: Authorized Signatory
	
	LENDERS:
	LAURUS MASTER FUND, LTD.
	VALENS U.S. SPV I, LLC
	VALENS OFFSHORE SPV I, LTD.
	VALENS OFFSHORE SPV II, CORP.
	ERATO
	PSOURCE STRUCTURED DEBT LIMITED
	
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ Samuel S. Duffey

	Name: Samuel S. Duffey
	Title: President
	Signed: November 2, 2011Loan Security Termination Agreement

 Exhibit 10.62 
 LOAN SECURITY TERMINATION AGREEMENT 
 (Biovest International, Inc.)

 THIS LOAN SECURITY TERMINATION AGREEMENT (this “Agreement”) is made as of December 15, 2011, by
and among LV ADMINISTRATIVE SERVICES, INC., as Administrative and Collateral Agent for the Lenders (“LV”), the LENDERS who are signatories hereto (the “Lenders”), and BIOVEST INTERNATIONAL, INC., a Delaware
corporation (“Biovest”). 
 RECITALS 

WHEREAS, on November 10, 2008, each of Biovest, Biovax, Inc., AutovaxID, Inc., Biolender, LLC and Biolender II, LLC (the
“Biovest Debtors”) commenced a voluntary case for reorganization under Chapter 11 of Title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. (the “Bankruptcy Code”), in the United States
Bankruptcy Court for the Middle District of Florida, Tampa Division (the “Bankruptcy Court”); 

WHEREAS, on August 16, 2010, the Biovest Debtors filed with the Bankruptcy Court their First Amended Joint Plan of
Reorganization of Biovest International, Inc., Biovax, Inc., AutovaxID, Inc., Biolender, LLC, and Biolender II, LLC under Chapter 11 of Title 11, United States Code dated as of August 16, 2010 (the “Biovest Joint Plan”), which
was modified by the First Modification to First Amended Joint Plan of Reorganization of Biovest International, Inc., Biovax, Inc., AutovaxID, Inc., Biolender, LLC, and Biolender II, LLC under Chapter 11 of Title 11, United States Code dated as of
October 25, 2010 (the “Biovest First Modification” and, together with the Biovest Joint Plan, the “Biovest Plan”); 
 WHEREAS, on November 2, 2010, the Bankruptcy Court entered its Order Confirming First Amended Joint Plan of Reorganization of Biovest International, Inc., Biovax, Inc., AutovaxID, Inc.,
Biolender, LLC, and Biolender II, LLC under Chapter 11 of Title 11, United States Code Dated as of August 16, 2010, as Modified, Pursuant to 11 U.S.C. §1129, and the effective date of the Biovest Plan occurred on November 17, 2010;

 WHEREAS, pursuant to the Biovest Plan, on November 17, 2010, LV, Laurus Master Fund Ltd. (In Liquidation), Erato
Corp., PSource Structured Debt Limited, Valens U.S. SPV I, LLC, Valens Offshore SPV I, Ltd., Valens Offshore SPV II, Corp., and Biovest entered into that certain Term Loan and Security Agreement (the “Loan Agreement”), pursuant to
which Laurus Master Fund Ltd. (In Liquidation), Erato Corp., PSource Structured Debt Limited, Valens U.S. SPV I, LLC, Valens Offshore SPV I, Ltd., and Valens Offshore SPV II, Corp. received (i) Secured Term A Notes of Biovest in an aggregate
principal amount of $24,900,000.00 (the “Term A Notes”), and/or (ii) Secured Term B Notes of Biovest in an aggregate principal amount of $4,160,000.00 (the “Term B Notes” and collectively with the Term A Notes,
the “Notes”); 
 WHEREAS, Erato Corp. has assigned its Term A Note dated November 17, 2010, in the
original principal amount of $1,333,334.00, to Calliope Capital Corp.; 
 WHEREAS, the Notes are secured by, among other
things, (i) that certain Grant of Security Interest in Intellectual Property dated as of November 17, 2010 by Analytica International, Inc. (“Analytica”) in favor of LV (the “IP Security Agreement”),
(ii) that certain Security Agreement dated November 17, 2010 by Analytica in favor of LV (the “Security Agreement”), and (iii) that certain Guaranty dated November 17, 2010 by Analytica in favor of LV (the
“Guaranty”); 

  
 -1-

 WHEREAS, on October 31, 2011, Analytica, LA-SER Alpha Group Sarl
(“LA-SER”) and Accentia Biopharmaceuticals, Inc. (“Accentia”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), which provides for the sale by Analytica, and the purchase by
LA-SER or its designee, of certain of the assets of Analytica free and clear of any liens, claims or encumbrances for an upfront purchase price of $4,000,000.00 plus an Earnout (as such term is defined in the Purchase Agreement); 

WHEREAS, on November 30, 2011, the Bankruptcy Court entered its Order Granting Reorganized Debtors’ Motion to Approve
Sale of Assets of Analytica, Inc., which authorized the execution, delivery and performance of the Purchase Agreement by Accentia and Analytica; and 
 WHEREAS, LV and Accentia entered into that certain letter agreement dated October 19, 2011 (the “Letter Agreement”) pursuant to which the parties agreed that LV and the
Lenders would release certain collateral securing the Notes and terminate certain agreements relating to Analytica in exchange for a payment of not less than $4,000,000.00 (the “Prepayment”), which payment shall be applied to pay
any accrued and unpaid interest on and to reduce the outstanding principal balances of certain secured term notes given by Accentia, an affiliate of Analytica, to PSource Structured Debt Limited, Valens U.S. SPV I, LLC, Calliope Capital Corp. (as
assignee of Erato Corp.) and Valens Offshore SPV II, Corp. pursuant to that certain Loan Prepayment, Modification and Security Termination Agreement of even date hereof. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

1. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Loan Agreement. 

2. The parties hereto agree that the above Recitals are true and correct in all respects. 

3. Upon the receipt of the Prepayment: 
  

	 	a.	LV hereby concurrently terminates the IP Security Agreement and the Security Agreement and releases and discharges any and all liens on the Collateral (as such term is
defined under the IP Security Agreement and the Security Agreement, as applicable) granted to LV under the IP Security Agreement and the Security Agreement as security for the Notes. 

 

	 	b.	LV hereby concurrently terminates the Guaranty and acknowledges and agrees that the Guaranty shall be of no further force and effect after the date hereof.

  

	 	c.	LV and the Lenders hereby irrevocably waive, release and give up all rights to or interests in any and all payments of the Earnout and to the Net Cash (as such term is
defined in the Purchase Agreement). 

 4. Except as specifically amended pursuant to this Agreement and the documents delivered in
connection herewith, the Loan Agreement and each Ancillary Agreement delivered in connection with the closing thereunder shall remain in full force and effect and are hereby ratified and confirmed, and the execution, delivery and effectiveness of
this Agreement shall not operate as a waiver of any right, power or remedy, nor constitute a waiver of any provision of the Loan Agreement or any Ancillary Agreement except as otherwise provided herein. 

5. LV agrees, from time to time after the date hereof, to execute and deliver to Biovest, at the sole cost and expense of Biovest, such
further instruments and documents and to take such further actions as may be reasonably necessary to fully effect the foregoing releases, discharges and terminations. LV and the Lenders acknowledge and agree that the foregoing releases, discharges
and terminations shall be fully binding on LV and the Lenders notwithstanding any provisions in the Loan Agreement or any Ancillary Agreement that require full payment of the Notes prior to the effectiveness of such releases, discharges and
terminations. 
 6. This Agreement shall be binding upon the parties hereto and their respective successors and assigns. The
parties hereto agree that this Agreement is fully and adequately supported by consideration, is fair and reasonable, and that they have had the opportunity to discuss this matter with counsel of their choice. This Agreement may be executed in one or
more counterparts, each of which shall be deemed an original and all of which together shall be deemed to constitute one agreement. It is understood and agreed that if facsimile copies of this Agreement bearing facsimile signatures or e-mails of PDF
copies of signatures are exchanged between the parties hereto, such copies shall in all respects have the same weight, force and legal effect and shall be fully as valid, binding, and enforceable as if such signed facsimile copies were original
documents bearing original signature. 
 7. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED, INTERPRETED AND ENFORCED
ACCORDING TO, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS PROVISIONS THEREOF. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT SHALL BE BROUGHT ONLY IN THE STATE COURTS OF NEW
YORK OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK. Wherever possible each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement
shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 

[remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the undersigned have executed this Loan Security Termination
Agreement as of the date first above written. 
  

			
	BIOVEST INTERNATIONAL, INC.
		
	 By:
	 	 /s/ David Moser

		 	      Name: David Moser
		 	      Title: Secretary

  

			
	LV ADMINISTRATIVE SERVICES, INC.
		
	 By:
	 	 /s/ Patrick Regan

		 	      Name: Patrick Regan
		 	      Title: Authorized Signatory

  

			
	PSOURCE STRUCTURED DEBT LIMITED
		
	 By:
	 	 : /s/ Patrick Regan

		 	      Name: Patrick Regan
		 	      Title: Authorized Signatory

  

			
	VALENS U.S. SPV I, LLC
	 By:
	 	 Valens Capital Management, LLC,
     its investment manager

  

			
	By:	 	 /s/ Patrick Regan

		 	      Name: Patrick Regan
		 	      Title: Authorized Signatory

  

			
	VALENS OFFSHORE SPV I, LTD.
	 By:
	 	 Valens Capital Management, LLC,
     its investment manager

  

			
	By:	 	 /s/ Patrick Regan

		 	      Name: Patrick Regan
		 	      Title: Authorized Signatory

 
			
	VALENS OFFSHORE SPV II, CORP.
	By:	 	Valens Capital Management, LLC,
		 	    its investment manager

  

			
	By:	 	 /s/ Patrick Regan

		 	      Name: Patrick Regan
		 	      Title: Authorized Signatory

  

			
	 LAURUS MASTER FUND LTD.
 (In Liquidation)

		
	By:	 	 /s/ Russell Smith

		 	      Name: Russell Smith
		 	      Title: Authorized Signatory

  

			
	 CALLIOPE CAPITAL CORP., as assignee
 of ERATO CORP.

		
	By:	 	 /s/ Patrick Regan

		 	      Name: Patrick Regan
		 	      Title: Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]